Ajani, J. A., Winter, K. A., Gunderson, L. L., Pedersen, J., Benson, A. B., 3rd, Thomas, C. R., Jr., . . . Willett, C. (2008). Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA, 299(16), 1914-1921.

Ajani, J. A., Winter, K. A., Gunderson, L. L., Pedersen, J., Benson, A. B., 3rd, Thomas, C. R., Jr., . . . Willett, C. G. (2010). Prognostic factors derived from a prospective database dictate clinical biology of anal cancer: the intergroup trial (RTOG 98-11). Cancer, 116(17), 4007-4013.

Akbari, R. P., Paty, P. B., Guillem, J. G., Weiser, M. R., Temple, L. K., Minsky, B. D., . . . Wong, W. D. (2004). Oncologic outcomes of salvage surgery for epidermoid carcinoma of the anus initially managed with combined modality therapy. Diseases of the Colon and Rectum, 47(7), 1136-1144.

Alam, N. N., White, D. A., Narang, S. K., Daniels, I. R., & Smart, N. J. (2016). Systematic review of guidelines for the assessment and management of high-grade anal intraepithelial neoplasia (AIN II/III). Colorectal Disease, 18(2), 135-146.

Alberta Provincial Gastrointestinal Tumour Team. (2013). Anal canal cancer (Clinical practice guideline GI-001 version 4). Alberta: Alberta health Services.

Amstutz, U., Henricks, L. M., Offer, S. M., Barbarino, J., Schellens, J. H. M., Swen, J. J., . . . Schwab, M. (2018). Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update. Clinical Pharmacology and Therapeutics, 103(2), 210-216.

Arana, R., Fléjou, J. F., Si-Mohamed, A., Bauer, P., & Etienney, I. (2015). Clinicopathological and virological characteristics of superficially invasive squamous-cell carcinoma of the anus. Colorectal Disease, 17(11), 965-972.

Bahng, A. Y., Dagan, A., Bruner, D. W., & Lin, L. L. (2012). Determination of prognostic factors for vaginal mucosal toxicity associated with intravaginal high-dose rate brachytherapy in patients with endometrial cancer. International Journal of Radiation Oncology, Biology, Physics, 82(2), 667-673.

Balamucki, C. J., Zlotecki, R. A., Rout, W. R., Newlin, H. E., Morris, C. G., Kirwan, J. M., . . . Mendenhall, W. M. (2011). Squamous cell carcinoma of the anal margin: the university of Florida experience. American Journal of Clinical Oncology, 34(4), 406-410.

Bartelink, H., Roelofsen, F., Eschwege, F., Rougier, P., Bosset, J. F., Gonzalez, D. G., . . . Pierart, M. (1997). Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. Journal of Clinical Oncology, 15(5), 2040-2049.

Ben-Josef, E., Moughan, J., Ajani, J. A., Flam, M., Gunderson, L., Pollock, J., . . . Willett, C. (2010). Impact of overall treatment time on survival and local control in patients with anal cancer: a pooled data analysis of Radiation Therapy Oncology Group trials 87-04 and 98-11. Journal of Clinical Oncology, 28(34), 5061-5066.

Benson, A. B., Venook, A. P., Al-Hawary, M. M., Cederquist, L., Chen, Y. J., Ciombor, K. K., . . . Freedman-Cass, D. A. (2018). Anal Carcinoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 16(7), 852-871.

Bentzen, A. G., Balteskard, L., Wanderås, E. H., Frykholm, G., Wilsgaard, T., Dahl, O., & Guren, M. G. (2013). Impaired health-related quality of life after chemoradiotherapy for anal cancer: late effects in a national cohort of 128 survivors. Acta Oncologica, 52(4), 736-744.

Bentzen, A. G., Guren, M. G., Vonen, B., Wanderas, E. H., Frykholm, G., Wilsgaard, T., . . . Balteskard, L. (2013). Faecal incontinence after chemoradiotherapy in anal cancer survivors: long-term results of a national cohort. Radiotherapy and Oncology, 108(1), 55-60.

Bentzen, A. G., Guren, M. G., Wanderas, E. H., Frykholm, G., Tveit, K. M., Wilsgaard, T., . . . Balteskard, L. (2012). Chemoradiotherapy of anal carcinoma: survival and recurrence in an unselected national cohort. International Journal of Radiation Oncology, Biology, Physics, 83(2), e173-180.

Bese, N. S., Hendry, J., & Jeremic, B. (2007). Effects of prolongation of overall treatment time due to unplanned interruptions during radiotherapy of different tumor sites and practical methods for compensation. International Journal of Radiation Oncology, Biology, Physics, 68(3), 654-661.

Bhuva, N. J., Glynne-Jones, R., Sonoda, L., Wong, W. L., & Harrison, M. K. (2012). To PET or not to PET? That is the question. Staging in anal cancer. Annals of Oncology, 23(8), 2078-2082.

Bilimoria, K. Y., Bentrem, D. J., Rock, C. E., Stewart, A. K., Ko, C. Y., & Halverson, A. (2009). Outcomes and prognostic factors for squamous-cell carcinoma of the anal canal: analysis of patients from the National Cancer Data Base. Diseases of the Colon and Rectum, 52(4), 624-631.

Brogden, D. R. L., Walsh, U., Pellino, G., Kontovounisios, C., Tekkis, P., & Mills, S. C. (2021). Evaluating the efficacy of treatment options for anal intraepithelial neoplasia: a systematic review. International Journal of Colorectal Disease, 36(2), 213-226.

Brown, E., Cray, A., Haworth, A., Chander, S., Lin, R., Subramanian, B., & Ng, M. (2015). Dose planning objectives in anal canal cancer IMRT: the TROG ANROTAT experience. Journal of medical radiation sciences, 62(2), 99-107.

Brown, G., Richards, C. J., Bourne, M. W., Newcombe, R. G., Radcliffe, A. G., Dallimore, N. S., & Williams, G. T. (2003). Morphologic predictors of lymph node status in rectal cancer with use of high-spatial-resolution MR imaging with histopathologic comparison. Radiology, 227(2), 371-377.

Bruland, O., Fluge, O., Immervoll, H., Balteskard, L., Myklebust, M., Skarstein, A., & Dahl, O. (2008). Gene expression reveals two distinct groups of anal carcinomas with clinical implications. British Journal of Cancer, 98(7), 1264-1273.

Cacheux, W., Lievre, A., De La Rochefordiere, A., Dieumegard, B., Cvitkovic, F., Labib, A., . . . Buecher, B. (2012). Chemotherapy in the treatment of anal canal carcinoma. Digestive and Liver Disease, 44(10), 803-811.

Cancer in Norway 2019: cancer incidence, mortality, survival and prevalence in Norway. (2020). Oslo: Cancer Registry of Norway.

Castor, M., da Silva, H. J., Gondim Martins, D. B., & de Mello, R. J. (2012). HPV and precancerous lesions of anal canal in women: systematic review. International Journal of Colorectal Disease, 27(3), 271-276.

Chan, R. J., Webster, J., Chung, B., Marquart, L., Ahmed, M., & Garantziotis, S. (2014). Prevention and treatment of acute radiation-induced skin reactions: a systematic review and meta-analysis of randomized controlled trials. BMC Cancer, 14, 53.

Chuong, M. D., Freilich, J. M., Hoffe, S. E., Fulp, W., Weber, J. M., Almhanna, K., . . . Shridhar, R. (2013). Intensity-Modulated Radiation Therapy vs. 3D Conformal Radiation Therapy for Squamous Cell Carcinoma of the Anal Canal. Gastrointestinal Cancer Research, 6(2), 39-45.

Clark, M. A., Hartley, A., & Geh, J. I. (2004). Cancer of the anal canal. Lancet Oncology, 5(3), 149-157.

Coffey, K., Beral, V., Green, J., Reeves, G., & Barnes, I. (2015). Lifestyle and reproductive risk factors associated with anal cancer in women aged over 50 years. British Journal of Cancer, 112(9), 1568-1574.

Cox, J. D., Stetz, J., & Pajak, T. F. (1995). Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). International Journal of Radiation Oncology, Biology, Physics, 31(5), 1341-1346.

Croke, J. M., & El-Sayed, S. (2012). Multidisciplinary management of cancer patients: chasing a shadow or real value? An overview of the literature. Current Oncology (Toronto, Ont.), 19(4), e232-238.

Dale, J. E., Sebjornsen, S., Leh, S., Rosler, C., Aaserud, S., Moller, B., . . . Dahl, O. (2017). Multimodal therapy is feasible in elderly anal cancer patients. Acta Oncologica, 56(1), 81-87.

Daling, J. R., Madeleine, M. M., Johnson, L. G., Schwartz, S. M., Shera, K. A., Wurscher, M. A., . . . McDougall, J. K. (2004). Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer. Cancer, 101(2), 270-280.

Dasgupta, T., Rothenstein, D., Chou, J. F., Zhang, Z., Wright, J. L., Saltz, L. B., . . . Goodman, K. A. (2013). Intensity-modulated radiotherapy vs. conventional radiotherapy in the treatment of anal squamous cell carcinoma: a propensity score analysis. Radiotherapy and Oncology, 107(2), 189-194.

Deenen, M. J., Dewit, L., Boot, H., Beijnen, J. H., Schellens, J. H., & Cats, A. (2013). Simultaneous integrated boost-intensity modulated radiation therapy with concomitant capecitabine and mitomycin C for locally advanced anal carcinoma: a phase 1 study. International Journal of Radiation Oncology, Biology, Physics, 85(5), e201-207.

Deenen, M. J., Meulendijks, D., Cats, A., Sechterberger, M. K., Severens, J. L., Boot, H., . . . Schellens, J. H. (2016). Upfront Genotyping of DPYD*2A to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis. Journal of Clinical Oncology, 34(3), 227-234.

DeFoe, S. G., Beriwal, S., Jones, H., Rakfal, S., Heron, D. E., Kabolizadeh, P., . . . Lalonde, R. (2012). Concurrent chemotherapy and intensity-modulated radiation therapy for anal carcinoma--clinical outcomes in a large National Cancer Institute-designated integrated cancer centre network. Clinical Oncology (Royal College of Radiologists), 24(6), 424-431.

DeFoe, S. G., Kabolizadeh, P., Heron, D. E., & Beriwal, S. (2013). Dosimetric parameters predictive of acute gastrointestinal toxicity in patients with anal carcinoma treated with concurrent chemotherapy and intensity-modulated radiation therapy. Oncology, 85(1), 1-7.

Dutta, S. W., Alonso, C. E., Waddle, M. R., Khandelwal, S. R., Janowski, E. M., & Trifiletti, D. M. (2018). Squamous cell carcinoma of the rectum: Practice trends and patient survival. Cancer medicine, 7(12), 6093-6103.

Dyson, T., & Draganov, P. V. (2009). Squamous cell cancer of the rectum. World Journal of Gastroenterology, 15(35), 4380-4386.

Edge, S. B., Byrd, D. R., Compton, C. C., Fritz, A. G., Greene, F. L., & Trotti, A. (2010). American Joint Committee on Cancer. Ajcc cancer staging handbook: from the AJCC cancer staging manual (7. utg.). New York: Springer

Eng, C., Chang, G. J., You, Y. N., Das, P., Rodriguez-Bigas, M., Xing, Y., . . . Wolff, R. A. (2014). The role of systemic chemotherapy and multidisciplinary management in improving the overall survival of patients with metastatic squamous cell carcinoma of the anal canal. Oncotarget, 5(22), 11133-11142.

Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research. (1996). Lancet, 348(9034), 1049-1054.

Erridge, S. C., Kerr, G. R., Downing, D., Duncan, W., & Price, A. (2002). The effect of overall treatment time on the survival and toxicity of radical radiotherapy for cervical carcinoma. Radiotherapy and Oncology, 63(1), 59-66.

Faivre, C., Rougier, P., Ducreux, M., Mitry, E., Lusinchi, A., Lasser, P., . . . Eschwege, F. (1999). Carcinome epidermoide metastatique de l'anus: etude retrospective de l'efficacite de l'association de 5-fluoro-uracile en perfusion continue et de cisplatine [5-fluorouracile and cisplatinum combination chemotherapy for metastatic squamous-cell anal cancer]. Bulletin du Cancer, 86(10), 861-865.

Fish, R., Sanders, C., Adams, R., Brewer, J., Brookes, S. T., DeNardo, J., . . . Renehan, A. G. (2018). A core outcome set for clinical trials of chemoradiotherapy interventions for anal cancer (CORMAC): a patient and health-care professional consensus. The lancet. Gastroenterology & hepatology, 3(12), 865-873.

Fox, P. A., Nathan, M., Francis, N., Singh, N., Weir, J., Dixon, G., . . . Bower, M. (2010). A double-blind, randomized controlled trial of the use of imiquimod cream for the treatment of anal canal high-grade anal intraepithelial neoplasia in HIV-positive MSM on HAART, with long-term follow-up data including the use of open-label imiquimod. AIDS, 24(15), 2331-2335.

Franco, P., Arcadipane, F., Ragona, R., Mistrangelo, M., Cassoni, P., Munoz, F., . . . Ricardi, U. (2016). Volumetric modulated arc therapy (VMAT) in the combined modality treatment of anal cancer patients. British Journal of Radiology, 89(1060), 20150832.

Fuchshuber, P. R., Rodriguez-Bigas, M., Weber, T., & Petrelli, N. J. (1997). Anal canal and perianal epidermoid cancers. Journal of the American College of Surgeons, 185(5), 494-505.

Gautier, M., Brochard, C., Lion, A., Henno, S., Mallet, A. L., Bodere, A., . . . Siproudhis, L. (2016). High-grade anal intraepithelial neoplasia: Progression to invasive cancer is not a certainty. Digestive and Liver Disease, 48(7), 806-811.

Gilbert, D. C., Serup-Hansen, E., Linnemann, D., Hogdall, E., Bailey, C., Summers, J., . . . Thomas, G. J. (2016). Tumour-infiltrating lymphocyte scores effectively stratify outcomes over and above p16 post chemo-radiotherapy in anal cancer. British Journal of Cancer, 114(2), 134-137.

Gilbert, D. C., Williams, A., Allan, K., Stokoe, J., Jackson, T., Linsdall, S., . . . Summers, J. (2013). p16INK4A, p53, EGFR expression and KRAS mutation status in squamous cell cancers of the anus: correlation with outcomes following chemo-radiotherapy. Radiotherapy and Oncology, 109(1), 146-151.

Glover, M., Smerdon, G. R., Andreyev, H. J., Benton, B. E., Bothma, P., Firth, O., . . . Yarnold, J. (2016). Hyperbaric oxygen for patients with chronic bowel dysfunction after pelvic radiotherapy (HOT2): a randomised, double-blind, sham-controlled phase 3 trial. Lancet Oncology, 17(2), 224-233.

Glynne-Jones, R., Meadows, H., Wan, S., Gollins, S., Leslie, M., Levine, E., . . . Sebag-Montefiore, D. (2008). EXTRA--a multicenter phase II study of chemoradiation using a 5 day per week oral regimen of capecitabine and intravenous mitomycin C in anal cancer. International Journal of Radiation Oncology, Biology, Physics, 72(1), 119-126.

Glynne-Jones, R., Nilsson, P. J., Aschele, C., Goh, V., Peiffert, D., Cervantes, A., & Arnold, D. (2014a). Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Radiotherapy and Oncology, 111(3), 330-339.

Glynne-Jones, R., Nilsson, P. J., Aschele, C., Goh, V., Peiffert, D., Cervantes, A., & Arnold, D. (2014b). Anal cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 25 Suppl 3, iii10-20.

Glynne-Jones, R., Sebag-Montefiore, D., Adams, R., McDonald, A., Gollins, S., James, R., . . . Jitlal, M. (2011). "Mind the gap"--the impact of variations in the duration of the treatment gap and overall treatment time in the first UK Anal Cancer Trial (ACT I). International Journal of Radiation Oncology, Biology, Physics, 81(5), 1488-1494.

Glynne-Jones, R., Sebag-Montefiore, D., Meadows, H. M., Cunningham, D., Begum, R., Adab, F., . . . Kadalayil, L. (2017). Best time to assess complete clinical response after chemoradiotherapy in squamous cell carcinoma of the anus (ACT II): a post-hoc analysis of randomised controlled phase 3 trial. Lancet Oncology, 18(3), 347-356.

Goh, V., Gollub, F. K., Liaw, J., Wellsted, D., Przybytniak, I., Padhani, A. R., & Glynne-Jones, R. (2010). Magnetic resonance imaging assessment of squamous cell carcinoma of the anal canal before and after chemoradiation: can MRI predict for eventual clinical outcome? International Journal of Radiation Oncology, Biology, Physics, 78(3), 715-721.

Goldman, S., Auer, G., Erhardt, K., & Seligson, U. (1987). Prognostic significance of clinical stage, histologic grade, and nuclear DNA content in squamous-cell carcinoma of the anus. Diseases of the Colon and Rectum, 30(6), 444-448.

Guerra, G. R., Kong, C. H., Warrier, S. K., Lynch, A. C., Heriot, A. G., & Ngan, S. Y. (2016). Primary squamous cell carcinoma of the rectum: An update and implications for treatment. World Journal of Gastrointestinal Surgery, 8(3), 252-265.

Guidelines for the management of anal cancer. I. (2007). Guidelines for the management of colorectal cancer (3. utg., s. 68-95). London: The Association of Coloproctology of Great Britain and Ireland.

Gunderson, L. L., Moughan, J., Ajani, J. A., Pedersen, J. E., Winter, K. A., Benson, A. B., 3rd, . . . Willett, C. G. (2013). Anal carcinoma: impact of TN category of disease on survival, disease relapse, and colostomy failure in US Gastrointestinal Intergroup RTOG 98-11 phase 3 trial. International Journal of Radiation Oncology, Biology, Physics, 87(4), 638-645.

Gunderson, L. L., Winter, K. A., Ajani, J. A., Pedersen, J. E., Moughan, J., Benson, A. B., 3rd, . . . Willett, C. G. (2012). Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin. Journal of Clinical Oncology, 30(35), 4344-4351.

Guren, M. G., Aagnes, B., Nygard, M., Dahl, O., & Moller, B. (2019). Rising Incidence and Improved Survival of Anal Squamous Cell Carcinoma in Norway, 1987-2016. Clinical Colorectal Cancer, 18(1), e96-e103.

Han, K., Cummings, B. J., Lindsay, P., Skliarenko, J., Craig, T., Le, L. W., . . . Kim, J. (2014). Prospective evaluation of acute toxicity and quality of life after IMRT and concurrent chemotherapy for anal canal and perianal cancer. International Journal of Radiation Oncology, Biology, Physics, 90(3), 587-594.

Hatfield, P., Cooper, R., & Sebag-Montefiore, D. (2008). Involved-field, low-dose chemoradiotherapy for early-stage anal carcinoma. International Journal of Radiation Oncology, Biology, Physics, 70(2), 419-424.

Hemminki, K., Liu, X., Ji, J., Sundquist, J., & Sundquist, K. (2012). Autoimmune disease and subsequent digestive tract cancer by histology. Annals of Oncology, 23(4), 927-933.

Henkenberens, C., Toklu, H., Tamme, C., & Bruns, F. (2016). Clinical Value of Squamous Cell Carcinoma Antigen (SCCAg) in Anal Cancer - A Single-Center Retrospective Analysis. Anticancer Research, 36(6), 3173-3177.

Higham, C. E., & Faithfull, S. (2015). Bone Health and Pelvic Radiotherapy. Clinical Oncology (Royal College of Radiologists), 27(11), 668-678.

Hodges, J. C., Das, P., Eng, C., Reish, A. G., Beddar, A. S., Delclos, M. E., . . . Crane, C. H. (2009). Intensity-modulated radiation therapy for the treatment of squamous cell anal cancer with para-aortic nodal involvement. International Journal of Radiation Oncology, Biology, Physics, 75(3), 791-794.

HPV-test gir enklere screening mot livmorhalskreft for 9 av 10 kvinner mellom 34 og 69 år. (2013). [nettdokument]. Oslo: Kreftregisteret. Hentet 23. aug. 2016.

HPV og HPV-vaksine. (2016). [nettside]. Oslo: Folkehelseinstituttet. Hentet 23. aug. 2016.

Humant papillomavirus (HPV), genitale infeksjoner - veileder for helsepersonell. (21. feb 2016). Smittevernveilederen [nettdokument]. Oslo: Folkehelseinstituttet. Hentet 23. aug 2016.

Incrocci, L., & Jensen, P. T. (2013). Pelvic radiotherapy and sexual function in men and women. Journal of Sexual Medicine, 10 Suppl 1, 53-64.

International Clinical Guideline Group. (2012). International guidelines on vaginal dilation after pelvic radiotherapy. Woodstock, UK: Owen Mumford.

Islami, F., Ferlay, J., Lortet-Tieulent, J., Bray, F., & Jemal, A. (2017). International trends in anal cancer incidence rates. International Journal of Epidemiology, 46(3), 924-938.

James, R. D., Glynne-Jones, R., Meadows, H. M., Cunningham, D., Myint, A. S., Saunders, M. P., . . . Sebag-Montefiore, D. (2013). Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 x 2 factorial trial. Lancet Oncology, 14(6), 516-524.

Jeong, B. G., Kim, D. Y., & Kim, S. Y. (2013). Concurrent chemoradiotherapy for squamous cell carcinoma of the rectum. Hepato-Gastroenterology, 60(123), 512-516.

Johnsson, A., Leon, O., Gunnlaugsson, A., Nilsson, P., & Hoglund, P. (2018). Determinants for local tumour control probability after radiotherapy of anal cancer. Radiotherapy and Oncology, 128(2), 380-386.

Julie, D. R., & Goodman, K. A. (2016). Advances in the Management of Anal Cancer. Current Oncology Reports, 18(3), 20.

Kachnic, L. A., Tsai, H. K., Coen, J. J., Blaszkowsky, L. S., Hartshorn, K., Kwak, E. L., . . . Hong, T. S. (2012). Dose-painted intensity-modulated radiation therapy for anal cancer: a multi-institutional report of acute toxicity and response to therapy. International Journal of Radiation Oncology, Biology, Physics, 82(1), 153-158.

Kachnic, L. A., Winter, K., Myerson, R. J., Goodyear, M. D., Willins, J., Esthappan, J., . . . Willett, C. G. (2013). RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal. International Journal of Radiation Oncology, Biology, Physics, 86(1), 27-33.

Kim, D. W., Byer, J., Kothari, N., Mahipal, A., Chang, Y. D., & Kim, R. D. (2017). EGFR Inhibitors in Patients with Advanced Squamous Cell Anal Carcinomas: A Single-Institution Experience. Oncology, 92(4), 190-196.

Kim, J. H., Beets, G. L., Kim, M. J., Kessels, A. G., & Beets-Tan, R. G. (2004). High-resolution MR imaging for nodal staging in rectal cancer: are there any criteria in addition to the size? European Journal of Radiology, 52(1), 78-83.

Kim, R., Byer, J., Fulp, W. J., Mahipal, A., Dinwoodie, W., & Shibata, D. (2014). Carboplatin and paclitaxel treatment is effective in advanced anal cancer. Oncology, 87(2), 125-132.

Kim, S., François, E., André, T., Samalin, E., Jary, M., El Hajbi, F., . . . Borg, C. (2018). Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study. Lancet Oncology, 19(8), 1094-1106.

Kochhar, R., Plumb, A. A., Carrington, B. M., & Saunders, M. (2012). Imaging of anal carcinoma. AJR: American Journal of Roentgenology, 199(3), W335-344.

Koh, D. M., Dzik-Jurasz, A., O'Neill, B., Tait, D., Husband, J. E., & Brown, G. (2008). Pelvic phased-array MR imaging of anal carcinoma before and after chemoradiation. British Journal of Radiology, 81(962), 91-98.

Krzowska-Firych, J., Lucas, G., Lucas, C., Lucas, N., & Pietrzyk, L. (2019). An overview of Human Papillomavirus (HPV) as an etiological factor of the anal cancer. Journal of infection and public health, 12(1), 1-6.

Kumar, S., Juresic, E., Barton, M., & Shafiq, J. (2010). Management of skin toxicity during radiation therapy: a review of the evidence. Journal of Medical Imaging and Radiation Oncology, 54(3), 264-279.

Lam, J. U., Rebolj, M., Dugue, P. A., Bonde, J., von Euler-Chelpin, M., & Lynge, E. (2014). Condom use in prevention of Human Papillomavirus infections and cervical neoplasia: systematic review of longitudinal studies. Journal of Medical Screening, 21(1), 38-50.

Leon, O., Guren, M., Hagberg, O., Glimelius, B., Dahl, O., Havsteen, H., . . . Johnsson, A. (2014). Anal carcinoma - Survival and recurrence in a large cohort of patients treated according to Nordic guidelines. Radiotherapy and Oncology, 113(3), 352-358.

Leon, O., Guren, M. G., Radu, C., Gunnlaugsson, A., & Johnsson, A. (2015). Phase I study of cetuximab in combination with 5-fluorouracil, mitomycin C and radiotherapy in patients with locally advanced anal cancer. European Journal of Cancer, 51(18), 2740-2746.

Leon, O., Hagberg, O., & Johnsson, A. (2018). Primary surgery with or without postoperative radiotherapy in early stage squamous cell carcinoma in the anal canal and anal margin. Acta Oncologica, 57(9), 1209-1215.

Lepinoy, A., Lescut, N., Puyraveau, M., Caubet, M., Boustani, J., Lakkis, Z., . . . Bosset, J. F. (2015). Evaluation of a 36 Gy elective node irradiation dose in anal cancer. Radiotherapy and Oncology, 116(2), 197-201.

Leve med kreft: nasjonal kreftstrategi (2018-2022). (2018). Oslo: Helse- og omsorgsdepartementet.

Liem, X., Saad, F., & Delouya, G. (2015). A Practical Approach to the Management of Radiation-Induced Hemorrhagic Cystitis. Drugs, 75(13), 1471-1482.

Lim, F., & Glynne-Jones, R. (2011). Chemotherapy/chemoradiation in anal cancer: a systematic review. Cancer Treatment Reviews, 37(7), 520-532.

Liu, Y., Sigel, K., & Gaisa, M. M. (2018). Human Papillomavirus Genotypes Predict Progression of Anal Low-Grade Squamous Intraepithelial Lesions. Journal of Infectious Diseases, 218(11), 1746-1752.

Lov om kommunale helse- og omsorgstjenester. LOV-2011-06-24-30.

Lukan, N., Ströbel, P., Willer, A., Kripp, M., Dinter, D., Mai, S., . . . Hofheinz, R. D. (2009). Cetuximab-based treatment of metastatic anal cancer: correlation of response with KRAS mutational status. Oncology, 77(5), 293-299.

Lund, J. A., Sundstrom, S. H., Haaverstad, R., Wibe, A., Svinsaas, M., & Myrvold, H. E. (2004). Endoanal ultrasound is of little value in follow-up of anal carcinomas. Diseases of the Colon and Rectum, 47(6), 839-842.

Macaya, A., Munoz-Santos, C., Balaguer, A., & Barbera, M. J. (2012). Interventions for anal canal intraepithelial neoplasia. The Cochrane database of systematic reviews, 12, CD009244.

Machalek, D. A., Poynten, M., Jin, F., Fairley, C. K., Farnsworth, A., Garland, S. M., . . . Grulich, A. E. (2012). Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: a systematic review and meta-analysis. Lancet Oncology, 13(5), 487-500.

Magdeburg, B., Fried, M., & Meyenberger, C. (1999). Endoscopic ultrasonography in the diagnosis, staging, and follow-up of anal carcinomas. Endoscopy, 31(5), 359-364.

Mai, S., Welzel, G., Ottstadt, M., Lohr, F., Severa, S., Prigge, E. S., . . . Reuschenbach, M. (2015). Prognostic Relevance of HPV Infection and p16 Overexpression in Squamous Cell Anal Cancer. International Journal of Radiation Oncology, Biology, Physics, 93(4), 819-827.

McMahon, C. J., Rofsky, N. M., & Pedrosa, I. (2010). Lymphatic metastases from pelvic tumors: anatomic classification, characterization, and staging. Radiology, 254(1), 31-46.

Meulendijks, D., Dewit, L., Tomasoa, N. B., van Tinteren, H., Beijnen, J. H., Schellens, J. H., & Cats, A. (2014). Chemoradiotherapy with capecitabine for locally advanced anal carcinoma: an alternative treatment option. British Journal of Cancer, 111(9), 1726-1733.

Meulendijks, D., Henricks, L. M., Sonke, G. S., Deenen, M. J., Froehlich, T. K., Amstutz, U., . . . Schellens, J. H. (2015). Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data. Lancet Oncology, 16(16), 1639-1650.

Meulendijks, D., Tomasoa, N. B., Dewit, L., Smits, P. H., Bakker, R., van Velthuysen, M. L., . . . Cats, A. (2015). HPV-negative squamous cell carcinoma of the anal canal is unresponsive to standard treatment and frequently carries disruptive mutations in TP53. British Journal of Cancer, 112(8), 1358-1366.

Miles, T. (2012). International Guidelines on Vaginal Dilation after Pelvic Radiotherapy. Brook Hill, Woodstock, Oxon: Owen Mumford Ltd.

Morris, V. K., Salem, M. E., Nimeiri, H., Iqbal, S., Singh, P., Ciombor, K., . . . Eng, C. (2017). Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. Lancet Oncology, 18(4), 446-453.

Muehlbauer, P. M., Thorpe, D., Davis, A., Drabot, R., Rawlings, B. L., & Kiker, E. (2009). Putting evidence into practice: evidence-based interventions to prevent, manage, and treat chemotherapy- and radiotherapy-induced diarrhea. Clinical Journal of Oncology Nursing, 13(3), 336-341.

Muirhead, R., Partridge, M., & Hawkins, M. A. (2015). A tumor control probability model for anal squamous cell carcinoma. Radiotherapy and Oncology, 116(2), 192-196.

Musio, D., De Felice, F., Manfrida, S., Balducci, M., Meldolesi, E., Gravina, G. L., . . . Valentini, V. (2015). Squamous cell carcinoma of the rectum: The treatment paradigm. European Journal of Surgical Oncology, 41(8), 1054-1058.

Myerson, R. J., Garofalo, M. C., El Naqa, I., Abrams, R. A., Apte, A., Bosch, W. R., . . . Kachnic, L. A. (2009). Elective clinical target volumes for conformal therapy in anorectal cancer: a radiation therapy oncology group consensus panel contouring atlas. International Journal of Radiation Oncology, Biology, Physics, 74(3), 824-830.

Nasjonal handlingsplan for kreft 2015-2017. (2015). (IS-2298). Oslo: Helsedirektoratet.

Nasjonal helse- og sykehusplan (2016−2019). (2015). (Meld. St. 11 (2015–2016)). Oslo: Helse- og omsorgsdepartemenetet.

Nasjonal strategi for kreftområdet 2006-2009. (2006). Oslo: Helse- og omsorgsdepartementet.

Ng, M., Ho, H., Skelton, J., Guerrieri, M., Guiney, M., Chao, M., . . . Melven, L. (2018). Intensity-modulated Radiotherapy for Anal Cancer: Dose-Volume Relationship of Acute Gastrointestinal Toxicity and Disease Outcomes. Clinical Oncology (Royal College of Radiologists), 30(10), 634-641.

Ng, M., Leong, T., Chander, S., Chu, J., Kneebone, A., Carroll, S., . . . Kachnic, L. (2012). Australasian Gastrointestinal Trials Group (AGITG) contouring atlas and planning guidelines for intensity-modulated radiotherapy in anal cancer. International Journal of Radiation Oncology, Biology, Physics, 83(5), 1455-1462.

Nguyen, B. T., Joon, D. L., Khoo, V., Quong, G., Chao, M., Wada, M., . . . Scott, A. (2008). Assessing the impact of FDG-PET in the management of anal cancer. Radiotherapy and Oncology, 87(3), 376-382.

Nigro, N. D. (1984). An evaluation of combined therapy for squamous cell cancer of the anal canal. Diseases of the Colon and Rectum, 27(12), 763-766.

Nigro, N. D., Vaitkevicius, V. K., & Considine, B., Jr. (1974). Combined therapy for cancer of the anal canal: a preliminary report. Diseases of the Colon and Rectum, 17(3), 354-356.

Nilsen, E., Alfsen, C. G., Feiring, B., Skjeldestad, F. E., Steen, R., & Sæterdal, I. (2007). Vaksiner mot humant papillomavirus (HPV): vurdering av effekt av profylaktiske HPV-vaksiner (Rapport fra Kunnskapssenteret Nr 5-2007). Oslo: Nasjonalt kunnskapssenter for helsetjenesten.

Nilsson, M. P., Nilsson, E. D., Johnsson, A., Leon, O., Gunnlaugsson, A., & Scherman, J. (2020). Patterns of recurrence in anal cancer: a detailed analysis. Radiation Oncology (London, England), 15(1), 125.

Nilsson, P. J., Svensson, C., Goldman, S., & Glimelius, B. (2002). Salvage abdominoperineal resection in anal epidermoid cancer. British Journal of Surgery, 89(11), 1425-1429.

Otto, S. D., Lee, L., Buhr, H. J., Frericks, B., Hocht, S., & Kroesen, A. J. (2009). Staging anal cancer: prospective comparison of transanal endoscopic ultrasound and magnetic resonance imaging. Journal of Gastrointestinal Surgery, 13(7), 1292-1298.

Parikh, J., Shaw, A., Grant, L. A., Schizas, A. M., Datta, V., Williams, A. B., & Griffin, N. (2011). Anal carcinomas: the role of endoanal ultrasound and magnetic resonance imaging in staging, response evaluation and follow-up. European Radiology, 21(4), 776-785.

Peron, J., Bylicki, O., Laude, C., Martel-Lafay, I., Carrie, C., & Racadot, S. (2015). Nonoperative management of squamous-cell carcinoma of the rectum. Diseases of the Colon and Rectum, 58(1), 60-64.

Pineda, C. E., & Welton, M. L. (2009). Management of anal squamous intraepithelial lesions. Clinics in Colon and Rectal Surgery, 22(2), 94-101.

Rao, S., Guren, M. G., Khan, K., Brown, G., Renehan, A. G., Steigen, S. E., . . . Arnold, D. (2021). Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, Jun 22 Epub ahead of print.

Rao, S., Sclafani, F., Eng, C., Adams, R. A., Guren, M. G., Sebag-Montefiore, D., . . . Cunningham, D. (2020). International Rare Cancers Initiative Multicenter Randomized Phase II Trial of Cisplatin and Fluorouracil Versus Carboplatin and Paclitaxel in Advanced Anal Cancer: InterAAct. Journal of Clinical Oncology, 38(22), 2510-2518.

Renehan, A. G., & O'Dwyer, S. T. (2011). Management of local disease relapse. Colorectal Disease, 13 Suppl 1, 44-52.

Renehan, A. G., Saunders, M. P., Schofield, P. F., & O'Dwyer, S. T. (2005). Patterns of local disease failure and outcome after salvage surgery in patients with anal cancer. British Journal of Surgery, 92(5), 605-614.

Richel, O., de Vries, H. J., van Noesel, C. J., Dijkgraaf, M. G., & Prins, J. M. (2013). Comparison of imiquimod, topical fluorouracil, and electrocautery for the treatment of anal intraepithelial neoplasia in HIV-positive men who have sex with men: an open-label, randomised controlled trial. Lancet Oncology, 14(4), 346-353.

Roach, S. C., Hulse, P. A., Moulding, F. J., Wilson, R., & Carrington, B. M. (2005). Magnetic resonance imaging of anal cancer. Clinical Radiology, 60(10), 1111-1119.

Rodel, F., Wieland, U., Fraunholz, I., Kitz, J., Rave-Frank, M., Wolff, H. A., . . . Rodel, C. (2015). Human papillomavirus DNA load and p16INK4a expression predict for local control in patients with anal squamous cell carcinoma treated with chemoradiotherapy. International Journal of Cancer, 136(2), 278-288.

Rogers, J. E., & Eng, C. (2017). Pharmacotherapy of Anal Cancer. Drugs, 77(14), 1519-1530.

Salerno, G., Daniels, I., Heald, R. J., Brown, G., & Moran, B. J. (2004). Management and imaging of low rectal carcinoma. Surgical Oncology, 13(2-3), 55-61.

Sammen - mot kreft: nasjonal kreftstrategi 2013-2017. (2013). Oslo: Helse- og omsorgsdepartementet.

Scholefield, J. H., Castle, M. T., & Watson, N. F. (2005). Malignant transformation of high-grade anal intraepithelial neoplasia. British Journal of Surgery, 92(9), 1133-1136.

Sclafani, F., & Rao, S. (2018). Systemic Therapies for Advanced Squamous Cell Anal Cancer. Current Oncology Reports, 20(7), 53.

Sekhar, H., Malcomson, L., Kochhar, R., Sperrin, M., Alam, N., Chakrbarty, B., . . . Renehan, A. G. (2020). Temporal improvements in loco-regional failure and survival in patients with anal cancer treated with chemo-radiotherapy: treatment cohort study (1990-2014). British Journal of Cancer, 122(6), 749-758.

Seneffekter etter kreftbehandling: faglige råd. (2017). (IS-2551). Oslo: Helsedirektoratet.

Serup-Hansen, E., Linnemann, D., Skovrider-Ruminski, W., Hogdall, E., Geertsen, P. F., & Havsteen, H. (2014). Human papillomavirus genotyping and p16 expression as prognostic factors for patients with American Joint Committee on Cancer stages I to III carcinoma of the anal canal. Journal of Clinical Oncology, 32(17), 1812-1817.

Shida, D., Kanemitsu, Y., Hamaguchi, T., & Shimada, Y. (2019). Introducing the eighth edition of the tumor-node-metastasis classification as relevant to colorectal cancer, anal cancer and appendiceal cancer: a comparison study with the seventh edition of the tumor-node-metastasis and the Japanese Classification of Colorectal, Appendiceal, and Anal Carcinoma. Japanese Journal of Clinical Oncology, 49(4), 321-328.

Shiels, M. S., Pfeiffer, R. M., Chaturvedi, A. K., Kreimer, A. R., & Engels, E. A. (2012). Impact of the HIV epidemic on the incidence rates of anal cancer in the United States. Journal of the National Cancer Institute, 104(20), 1591-1598.

Slørdahl, K. S., Klotz, D., Olsen, J., Skovlund, E., Undseth, C., Abildgaard, H. L., . . . Guren, M. G. (2021). Treatment outcomes and prognostic factors after chemoradiotherapy for anal cancer. Acta Oncologica, Dec 15 [Epub ahead of print].

Sodergren, S. C., Johnson, C. D., Gilbert, A., Tomaszewski, K. A., Chu, W., Chung, H. T., . . . Vassiliou, V. (2018). Phase I-III development of the EORTC QLQ-ANL27, a health-related quality of life questionnaire for anal cancer. Radiotherapy and Oncology, 126(2), 222-228.

Sodergren, S. C., Vassiliou, V., Dennis, K., Tomaszewski, K. A., Gilbert, A., Glynne-Jones, R., . . . Johnson, C. D. (2015). Systematic review of the quality of life issues associated with anal cancer and its treatment with radiochemotherapy. Supportive Care in Cancer, 23(12), 3613-3623.

Spithoff, K., Cummings, B., Jonker, D., & Biagi, J. J. (2014). Chemoradiotherapy for squamous cell cancer of the anal canal: a systematic review. Clinical Oncology (Royal College of Radiologists), 26(8), 473-487.

Statistik om analkræft. (12. august 2019). [nettside]. København: Kræftens Bekæmpelse. Hentet 6. april 2021.

Stoker, J., Rociu, E., Wiersma, T. G., & Lameris, J. S. (2000). Imaging of anorectal disease. British Journal of Surgery, 87(1), 10-27.

Sturgeon, J. D., Crane, C. H., Krishnan, S., Minsky, B. D., Skibber, J. M., Rodriguez-Bigas, M. A., . . . Das, P. (2017). Definitive Chemoradiation for Squamous Cell Carcinoma of the Rectum. American Journal of Clinical Oncology, 40(2), 163-166.

Sun, G., Dong, X., Tang, X., Qu, H., Zhang, H., & Zhao, E. (2018). The prognostic value of HPV combined p16 status in patients with anal squamous cell carcinoma: a meta-analysis. Oncotarget, 9(8), 8081-8088.

Sunesen, K. G., Norgaard, M., Thorlacius-Ussing, O., & Laurberg, S. (2010). Immunosuppressive disorders and risk of anal squamous cell carcinoma: a nationwide cohort study in Denmark, 1978-2005. International Journal of Cancer, 127(3), 675-684.

Tahir, A. R., Westhuyzen, J., Dass, J., Collins, M. K., Webb, R., Hewitt, S., . . . McKay, M. (2015). Hyperbaric oxygen therapy for chronic radiation-induced tissue injuries: Australasia's largest study. Asia-Pacific Journal of Clinical Oncology, 11(1), 68-77.

Taylor, A., Rockall, A. G., Reznek, R. H., & Powell, M. E. (2005). Mapping pelvic lymph nodes: guidelines for delineation in intensity-modulated radiotherapy. International Journal of Radiation Oncology, Biology, Physics, 63(5), 1604-1612.

The Royal College of Radiologists. (20019). The timely delivery of radical radiotherapy: standards and guidelines for the management of unscheduled treatment interruptions (4. utg.). London: The Royal College of Radiologist.

Thind, G., Johal, B., Follwell, M., & Kennecke, H. F. (2014). Chemoradiation with capecitabine and mitomycin-C for stage I-III anal squamous cell carcinoma. Radiation Oncology (London, England), 9, 124.

TNM Classification of Malignant Tumours. (2017). (8. utg.). New York: John Wiley & Sons.

Vanneste, B. G., Van De Voorde, L., de Ridder, R. J., Van Limbergen, E. J., Lambin, P., & van Lin, E. N. (2015). Chronic radiation proctitis: tricks to prevent and treat. International Journal of Colorectal Disease, 30(10), 1293-1303.

Wade, D. S., Herrera, L., Castillo, N. B., & Petrelli, N. J. (1989). Metastases to the lymph nodes in epidermoid carcinoma of the anal canal studied by a clearing technique. Surgery, Gynecology and Obstetrics, 169(3), 238-242.

Watson, A. J., Smith, B. B., Whitehead, M. R., Sykes, P. H., & Frizelle, F. A. (2006). Malignant progression of anal intra-epithelial neoplasia. ANZ Journal of Surgery, 76(8), 715-717.

Wells, I. T., & Fox, B. M. (2012). PET/CT in anal cancer - is it worth doing? Clinical Radiology, 67(6), 535-540.

WHO Classification of Tumours of the Digestive System. (2010). (4. utg.). Lyon: International Agency for Research on Cancer.

Wildiers, H., Heeren, P., Puts, M., Topinkova, E., Janssen-Heijnen, M. L., Extermann, M., . . . Hurria, A. (2014). International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer. Journal of Clinical Oncology, 32(24), 2595-2603.

Winer, R. L., Hughes, J. P., Feng, Q., O'Reilly, S., Kiviat, N. B., Holmes, K. K., & Koutsky, L. A. (2006). Condom use and the risk of genital human papillomavirus infection in young women. New England Journal of Medicine, 354(25), 2645-2654.

Zidar, N., Langner, C., Odar, K., Hošnjak, L., Kamaradova, K., Daum, O., . . . Poljak, M. (2017). Anal verrucous carcinoma is not related to infection with human papillomaviruses and should be distinguished from giant condyloma (Buschke-Lowenstein tumour). Histopathology, 70(6), 938-945.

zur Hausen, H. (2000). Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. Journal of the National Cancer Institute, 92(9), 690-698.

Aass, N., Haugne, D. F., Rosland, J. H., HJordhøy, M., Dønnem, T., & Knudsen, A. K. (2015). Nasjonalt handlingsprogram med retningslinjer for palliasjon i kreftomsorgen (5. utg.). (IS-2285). Oslo: Helsedirektoratet.